Chemistry and Drug Metabolism Section, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland, USA.
Am J Addict. 2013 Sep-Oct;22(5):510-4. doi: 10.1111/j.1521-0391.2013.12003.x.
Δ9-tetrahydrocannabinol (THC) promotes sleep in animals; clinical use of THC is associated with somnolence. Human laboratory studies of oral THC have not shown consistent effects on sleep. We prospectively evaluated self-reported sleep parameters during controlled oral THC administration to research volunteers.
Thirteen male chronic daily cannabis smokers (mean ± SD age 24.6± 3.7 years, self-reported smoking frequency of 5.5 ± 5.9 (range 1-24) joint-equivalents daily at study entry) were administered oral THC doses (20 mg) around-the-clock for 7 days (40-120 mg daily) starting the afternoon after admission. The St. Mary's Hospital Sleep Questionnaire was completed every morning. Plasma THC and 11-OH-THC (active metabolite) concentrations were measured in venous blood samples collected every evening. Changes in sleep characteristics over time and associations between sleep characteristics and plasma cannabinoid concentrations were evaluated with repeated measures mixed linear regression.
Higher evening THC and 11-OH-THC concentrations were significantly associated with shorter sleep latency, less difficulty falling asleep, and more daytime sleep the following day. In contrast, the duration of calculated and self-reported nighttime sleep decreased slightly (3.54 and 5.34 minutes per night, respectively) but significantly during the study.
These findings suggest that tolerance to the somnolent effects of THC may have occurred, but results should be considered preliminary due to design limitations.
Somnolence from oral THC may dissipate with chronic, high-dose use. This has implications for patients who may take chronic oral THC for medicinal purposes, including cannabis dependence treatment. (Am J Addict 2013;22:510-514).
Δ9-四氢大麻酚(THC)可促进动物睡眠;临床使用 THC 与嗜睡有关。口服 THC 的人体实验室研究并未显示对睡眠有一致的影响。我们前瞻性地评估了在研究志愿者口服 THC 期间自我报告的睡眠参数。
13 名男性慢性每日吸食大麻的吸烟者(平均年龄±标准差 24.6±3.7 岁,研究开始时自我报告的吸烟频率为 5.5±5.9(范围 1-24)个大麻烟等效物/天)每天接受口服 THC 给药(20mg),持续 7 天(40-120mg/天),从入院后的下午开始。每天早上完成圣玛丽医院睡眠问卷。每天晚上采集静脉血样测量血浆 THC 和 11-OH-THC(活性代谢物)浓度。使用重复测量混合线性回归评估睡眠特征随时间的变化以及睡眠特征与血浆大麻素浓度之间的关系。
傍晚时的 THC 和 11-OH-THC 浓度越高,入睡潜伏期越短,入睡越困难,第二天白天的睡眠时间也越长。相比之下,计算出的和自我报告的夜间睡眠时间略有减少(每晚分别减少 3.54 和 5.34 分钟),但在研究期间显著减少。
这些发现表明,可能已经对 THC 的催眠作用产生了耐受性,但由于设计限制,结果应被视为初步结果。
口服 THC 的催眠作用可能会随着慢性、高剂量使用而消失。这对可能因医疗目的(包括大麻依赖治疗)而长期口服 THC 的患者具有重要意义。